OneCell Diagnostics today announced its launch of OncoIncytes, a comprehensive multi-modal cancer diagnostic panel that integrates multiple types of data including Circulating Tumor DNA (ctDNA), Circulating Tumor Cells (CTCs) at single cell resolution, RNA transcriptomics and Proteomics (150 proteins at the single cell level).

OneCell Diagnostics今天宣布推出OncoIncytes，这是一款综合多模式癌症诊断面板，整合了多种类型的数据，包括循环肿瘤DNA（ctDNA）、单细胞分辨率的循环肿瘤细胞（CTCs）、RNA转录组学和蛋白质组学（单细胞水平的150种蛋白质）。

Marking its evolution from a genomics-based diagnostic company to an AI-powered leader in precision oncology, the firm is also rebranding as 1Cell.Ai, focused on combining its deep science expertise with advanced data science capabilities. .

标志着该公司从一家基于基因组学的诊断公司发展为人工智能驱动的精准肿瘤学领导者，该公司还进行了品牌重塑，更名为1Cell.Ai，专注于将其深厚的科学专业知识与先进的数据科学能力相结合。

'By integrating true single cell level multi-omics data with ctDNA, OncoIncytes provides unparalleled information to oncologists that enhances critical clinical decisions,' said

“通过将真正的单细胞水平多组学数据与ctDNA相结合，OncoIncytes为肿瘤学家提供了无与伦比的信息，有助于优化关键的临床决策，”

Mohan Uttarwar

莫汉·乌塔瓦尔

, CEO and co-founder of 1Cell.Ai. 'This approach offers unprecedented sensitivity and specificity to optimize clinical trial successes, particularly in early-stage research. For antibody-drug conjugate studies, this represents a unique way to select the most appropriate patients, and address one of the most significant challenges in translational research.'.

，1Cell.Ai的首席执行官兼联合创始人。“这种方法提供了前所未有的灵敏度和特异性，以优化临床试验的成功率，尤其是在早期研究阶段。对于抗体药物偶联物研究而言，这是一种选择最适合患者的独特方法，并解决了转化研究中最大的挑战之一。”

OncoIncytes' technology employs a 1080 gene panel and leverages artificial intelligence and machine learning models to deliver deeper insights into clinical decision-making. Its primary innovation enables pharmaceutical and biotech companies to advance antibody-drug conjugates (ADCs) development during early-stage clinical studies by detecting protein expression on cell surfaces that other liquid biopsy tests cannot identify.

OncoIncytes的技术采用了一个1080基因面板，并利用人工智能和机器学习模型，为临床决策提供更深入的见解。其主要创新在于，通过检测其他液体活检测试无法识别的细胞表面蛋白表达，帮助制药和生物技术公司在早期临床研究中推动抗体药物偶联物（ADC）的开发。

The technology is transforming cancer research, drug development, patient selection, and therapy response monitoring with unprecedented granularity. Healthcare providers can now request sample collection kits to be shipped to the 1Cell.Ai lab from hospitals and clinical trial sites. Once samples are collected, the team processes the data and uploads results through their iDiscover application with maximum accuracy and expediency.

这项技术正在以空前的精细程度转变癌症研究、药物开发、患者选择和治疗反应监测。医疗保健提供者现在可以请求将样本采集工具包从医院和临床试验地点运送到1Cell.Ai实验室。一旦样本被收集，团队就会处理数据并通过其iDiscover应用程序以最高准确性和速度上传结果。

Our laboratory at .

我们的实验室在。

Foster City

福斯特城

has recently been CLIA-certified.

最近获得了CLIA认证。

The 1080 gene panel was validated against an orthogonal NGS panel, Illumina's TSO 500 and the FDA cleared PGDx panel at Dr.

1080基因面板针对一个正交的NGS面板、Illumina的TSO 500以及FDA批准的PGDx面板进行了验证。

Ravindra Kohle's

拉温德拉·科尔的

laboratory at

实验室在

Augusta

奥古斯塔

University's

大学的

Medical College of Georgia

乔治亚医学院

and was shown to have a 100% concordance between the results comparing the methodologies.

并且显示在比较方法论的结果之间有100%的一致性。

'Our commitment to democratizing precision oncology through more accessible, actionable, and affordable diagnostic cancer testing remains stronger than ever,' added Uttarwar. 'The rebranding to 1Cell.Ai reflects our expanded mission to revolutionize cancer care through artificial intelligence, moving beyond diagnostics to more comprehensive AI-powered precision oncology solutions.'.

“我们通过更易获取、更具操作性且更实惠的癌症诊断测试来推动精准肿瘤学普及的承诺比以往任何时候都更加坚定，”乌塔尔瓦尔补充道。“品牌重塑为1Cell.Ai反映了我们通过人工智能彻底改变癌症治疗的扩展使命，超越诊断，迈向更全面的由人工智能驱动的精准肿瘤学解决方案。”

The launch of this powerful new technology and the repositioning follows 1Cell.Ai's recent oversubscribed

这项强大新技术的推出和重新定位，紧随1Cell.Ai近期超额认购之后。

$16M

1600万美元

Series A funding round, as well as the introduction of its clinical advisory board of global cancer experts, chaired by Nobel Laureate Dr.

A轮融资，以及其由诺贝尔奖获得者Dr.担任主席的全球癌症专家临床顾问委员会的成立。

James Rothman

詹姆斯·罗斯曼

About 1Cell.Ai

关于1Cell.Ai

1Cell.Ai is a precision oncology company pioneering the next generation of cancer diagnostics through patented single cell multi-omics and cell biopsy technology. By combining groundbreaking science with AI-enabled biomarker discovery, 1Cell.Ai creates a new standard in precision oncology at the single cell level.

1Cell.Ai 是一家精准肿瘤学公司，通过获得专利的单细胞多组学和细胞活检技术，开创了下一代癌症诊断方法。通过将突破性的科学与人工智能驱动的生物标志物发现相结合，1Cell.Ai 在单细胞层面上树立了精准肿瘤学的新标准。